692 related articles for article (PubMed ID: 16905365)
1. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
2. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
3. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
7. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
[TBL] [Abstract][Full Text] [Related]
8. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield MS
Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy of severe combined immunodeficiencies.
Cavazzana-Calvo M; Hacein-Bey S; Yates F; de Villartay JP; Le Deist F; Fischer A
J Gene Med; 2001; 3(3):201-6. PubMed ID: 11437325
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow gene therapy for adenosine deaminase deficiency.
Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
[TBL] [Abstract][Full Text] [Related]
12. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y
Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for hematopoietic and immune disorders.
Kohn DB
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S55-8. PubMed ID: 8971410
[TBL] [Abstract][Full Text] [Related]
14. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
Ferrua F; Brigida I; Aiuti A
Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
[TBL] [Abstract][Full Text] [Related]
15. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
16. Update on gene therapy for hereditary hematological disorders.
Herzog RW; Arruda VR
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):215-32. PubMed ID: 15030282
[TBL] [Abstract][Full Text] [Related]
17. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
Hacein-Bey-Abina S; Le Deist F; Carlier F; Bouneaud C; Hue C; De Villartay JP; Thrasher AJ; Wulffraat N; Sorensen R; Dupuis-Girod S; Fischer A; Davies EG; Kuis W; Leiva L; Cavazzana-Calvo M
N Engl J Med; 2002 Apr; 346(16):1185-93. PubMed ID: 11961146
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
19. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
[TBL] [Abstract][Full Text] [Related]
20. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
